Foundayo Launch Data Missing from Q1, Lilly Shares Down 19% YTD
Foundayo's early April launch excludes its sales from first-quarter results, leaving investors waiting five to six weeks of prescription data to assess its uptake versus Wegovy. Lilly's shares are down 19% year-to-date as investors weigh its obesity franchise, while analysts forecast 26% revenue growth from diabetes and obesity drugs.
1. Foundayo Launch Excludes Q1 Data
Foundayo began U.S. sales in early April, so its prescription volumes are not reflected in Lilly's reported first-quarter revenue. Investors must wait for several more weeks of data to gauge customer adoption and market penetration compared with competitors.
2. Data Requirements for Early Sales Read
Analysts and investors indicate that five to six weeks of prescription tracking are needed to form a clear picture of Foundayo's initial market performance. Early feedback suggests its uptake may lag the oral Wegovy launch, but full conclusions remain premature.
3. Share Performance and Revenue Outlook
Lilly's share price has declined 19% year-to-date as market participants weigh the strength of its obesity portfolio, which also includes Zepbound and Mounjaro. Meanwhile, analysts project a 26% increase in full-year revenue driven by strong global demand for diabetes and obesity treatments.